Procarta
Biosystems
Ltd.
Biosystems
Ltd.
Pioneering DNA-based therapies (TFDs) to treat infectious diseases, including the major health issue of the 21st
century, "Superbugs".
Welcome to Procarta Biosystems
Company Profile
Procarta Biosystems is targeting the major healthcare problem of antibiotic drug resistance by deploying its proprietary transcription factor decoys (TFDs) against the resistance mechanisms of superbugs, such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci).The Company is based on the world renowned expertise in microbial genome regulation of its founding scientists at the John Innes Centre in the UK...
TFD/antibiotic combinations
Procarta's first product development is a TFD to be used in combination with vancomycin to combat resistance to this antibiotic and others of the glycopeptide class.Vancomycin is referred to as the antibiotic of 'last resort' because of its use in the hospital setting, in particular in intensive care units, to combat serious infections such as MRSA...
Antibiotic resistance
Antibiotic drugs are a marked success: in the past 50 years they have driven down deaths due to bacterial infection and are increasingly relied upon to do so today.However the rise of multi-drug resistant bacteria and difficult or impossible to treat 'superbugs' may herald the end of the antibiotic era...